brivaracetam: Clinical Trials

10 trials of brivaracetam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 not yet recruiting, 1 terminated. 10 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 8, Not yet recruiting 1, Terminated 1
Phase 12Completed 1, Not yet recruiting 1

Follow brivaracetam: new trials by email Literature Review of brivaracetam trials Research Report on brivaracetam

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epileptic Hippocampus in Alzheimer's Disease
Brivaracetam - Alzheimer Disease, Mild Cognitive Impairment
Phase 1 / Phase 2Not yet recruitingUniversity of California, Los Angeles252026-01-012026-01-27
Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Brivaracetam, Placebo - Spinal Cord Injuries
Phase 1 / Phase 2CompletedUniversity of Minnesota242021-02-012025-10-14
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
Brivaracetam - Epilepsy
Phase 2CompletedUCB Biopharma S.P.R.L.502018-06-012022-05-11
A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Brivaracetam, Lorazepam - Epilepsy
Phase 2CompletedUCB Biopharma S.P.R.L.462017-02-062020-12-16
Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures
Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution - Nonconvulsive Electrographic Seizures
Phase 2TerminatedUCB BIOSCIENCES, Inc.12014-03-012018-07-11
Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
Brivaracetam - Epilepsy
Phase 2CompletedUCB Pharma1002011-07-012018-07-11
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
Placebo, Brivaracetam - Epilepsy
Phase 2CompletedUCB Pharma2102005-11-072018-10-02
A Study of Brivaracetam in Subjects With Partial Onset Seizures
Placebo, Brivaracetam - Epilepsy, Focal
Phase 2CompletedUCB Pharma1572005-05-012015-04-13
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
Placebo, Brivaracetam - Neuralgia, Postherpetic
Phase 2CompletedUCB Pharma1522004-10-112019-01-31
Effect of Brivaracetam in Photosensitive Epileptic Subjects
Brivaracetam - Epilepsy
Phase 2CompletedUCB Pharma202002-09-012009-12-01

Conditions studied

Epilepsy (6)  ·  Alzheimer Disease (1)  ·  Cognitive Dysfunction (1)  ·  Epilepsies, Partial (1)  ·  Neuralgia, Postherpetic (1)  ·  Spinal Cord Injuries (1)

Sponsors

UCB Pharma (5)  ·  UCB Biopharma S.P.R.L. (2)  ·  UCB BIOSCIENCES, Inc. (1)  ·  University of California, Los Angeles (1)  ·  University of Minnesota (1)

Countries

United States (7)  ·  Czechia (4)  ·  Germany (4)  ·  Spain (4)  ·  Belgium (3)  ·  France (3)  ·  Mexico (3)  ·  Poland (3)  ·  United Kingdom (2)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Finland (1)  ·  Hungary (1)  ·  India (1)  ·  Italy (1)

Top investigators

Keith A Vossel, MD, MSc (1)  ·  Leslie Morse, DO (1)  ·  Philipp von Rosenstiel, MD. (1)  ·  Scott Falci, MD (1)

Results publications

PMID 31937513, PMID 35285519, PMID 22813235, PMID 27265725, PMID 33461041, PMID 34570177, PMID 35196395

NIH funding

2004 (2), 2016 (1)